The Evolution of Gynecologic Cancer Care: Progress, Persistent Gaps, and the Next Frontier

By Zoran Gatalica, Medical Director, Reference Medicine

Semir Vranić, College of Medicine, QU Health, Qatar University, Doha, Qatar

Gynecologic cancers remain a major global health challenge despite decades of scientific progress. Cervical and endometrial cancers alone account for more than one million new diagnoses annually worldwide, underscoring the ongoing burden of disease and the need for more effective prevention, earlier detection, and increasingly individualized treatment strategies. Cervical cancer accounted for approximately 660,000 new cases of gynecologic cancers globally in 2022, while endometrial cancer contributed more than 420,000 additional diagnoses worldwide.^1,2

At the same time, the landscape of women’s oncology has changed profoundly. Over the last two decades, advances in screening, vaccination, molecular diagnostics, targeted therapies, and immunotherapy have transformed how gynecologic cancers are prevented, identified, and treated. In several cancers, clinical management is shifting away from a uniform treatment paradigm toward one increasingly guided by tumor biology, inherited risk, and predictive biomarkers.

This progress has not been evenly distributed across all gynecologic malignancies. While cervical cancer incidence has markedly declined in many regions because of prevention efforts, ovarian cancer remains the deadliest gynecologic cancer because effective population-wide early detection strategies remain elusive.³ Yet even in areas where outcomes have historically lagged, emerging technologies—including blood-based detection assays, molecular profiling, and precision therapeutics—are creating new possibilities.

The future of gynecologic oncology will likely depend less on reacting to advanced disease and more on preventing cancer, identifying risk earlier, and tailoring therapy to the unique biology of each patient and tumor.

Prevention as the Most Effective Strategy

Some of the greatest improvements in women’s cancer outcomes have resulted not from new drugs, but from preventing malignancy before it develops.

The Pap test remains one of the most consequential advances in women’s health, fundamentally changing cervical cancer prevention by enabling clinicians to identify and treat precancerous lesions before invasive disease emerges.¹ Widespread cervical screening contributes substantially to reductions in cervical cancer incidence and mortality in countries with organized screening programs. ¹

More recently, prevention efforts have expanded beyond screening to vaccination. Persistent infection with high-risk human papillomavirus (HPV) causes nearly all cervical cancers globally. ¹ Since HPV vaccination programs began in 2006, population-level declines in HPV infection have been substantial. A large meta-analysis demonstrated reductions in HPV-16/18 prevalence of 83% among girls aged 13–19 years and 66% among women aged 20–24 years following vaccine implementation.⁴

Current HPV vaccines (e.g., Gardasil 9) may prevent most cervical cancers associated with covered HPV strains when administered before viral exposure.^1,4 Importantly, the benefits of vaccination are no longer theoretical; reductions in cervical precancers and invasive disease are increasingly being observed in vaccinated populations.

These developments illustrate a broader shift in oncology: durable improvements in outcomes may depend as much on prevention and risk reduction as on treatment advances.

The Persistent Challenge of Widespread Early Detection

Scientific progress has been uneven across gynecologic cancers. Ovarian cancer, in particular, remains one of the most difficult malignancies to identify early.

Unlike cervical cancer, ovarian cancer lacks validated screening approaches suitable for routine use in average-risk populations.³ Symptoms — including bloating, abdominal discomfort, and early satiety — are often nonspecific and easily overlooked. Consequently, approximately 70% of ovarian cancers are diagnosed after the disease has spread beyond the ovaries, substantially worsening prognosis. ³

The impact of delayed diagnosis is considerable. Five-year survival exceeds 90% when ovarian cancer is identified at localized stages, but declines dramatically following advanced-stage detection. ³

Historically investigated biomarkers, such as CA-125, have clinical value but have not proven sufficiently sensitive or specific for population-wide screening. Early-stage tumors may not produce detectable elevations, while benign conditions can yield false-positive results, limiting the usefulness as a broad screening tool. ³ More recently, HE4 (Human Epididymis Protein 4) has emerged as a promising blood-based biomarker for early detection of ovarian cancer. It showed the pooled sensitivity and specificity for diagnosing ovarian cancer of 83% and 90%, respectively.⁵ 

Blood-Based Detection and the Promise—And Limitations—of MCED Testing

The search for earlier diagnosis has accelerated interest in blood-based cancer detection technologies.

Multi-cancer early detection (MCED) assays aim to identify circulating tumor-derived biomarkers before symptoms emerge and may eventually expand screening opportunities beyond current organ-specific approaches.⁶ Such technologies could prove especially important for cancers with limited early detection pathways, including ovarian and certain endometrial cancers.

However, enthusiasm remains tempered by important unanswered questions.

MCED assays are not currently recommended as routine screening tools for hereditary high-risk populations because evidence remains insufficient to demonstrate improved survival or reduced mortality beyond established surveillance strategies.⁶ Concerns persist regarding false positives, overdiagnosis, downstream diagnostic procedures, and optimal integration into existing care models. ⁶

An increasingly plausible future application may not be universal screening, but targeted deployment among carefully selected populations with elevated inherited or acquired risk and few existing surveillance options.

As with many emerging technologies in oncology, clinical utility—not technical capability alone—will ultimately determine adoption.

From One-Size-Fits-All Treatment to Biomarker-Guided Therapy

Historically, treatment decisions in oncology, including gynecologic oncology, were driven primarily by tumor location and stage. Increasingly, they are being guided by molecular characteristics.

This shift reflects growing recognition that tumors originating in the same organ may behave very differently biologically and respond differently to treatment.^7,8

Endometrial cancers, the most common gynecologic malignancy worldwide, exhibiting mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) biology, often demonstrate greater responsiveness to immune checkpoint inhibition, illustrating how molecular classification can influence therapeutic decisions. ^7,8

Similarly, in ovarian cancer, testing for BRCA1/2 mutations and homologous recombination deficiency (HRD) has expanded opportunities for hereditary cancer identification and use of targeted therapies, including Poly(ADP-ribose) polymerase (PARP) inhibitors.³

Precision medicine increasingly seeks to answer a fundamental question: Which patients will benefit most from which therapies while minimizing unnecessary toxicity?

Future progress may depend not only on escalating treatment intensity, but in selected patients, safely reducing it.

How Immunotherapy Is Changing Gynecologic Cancer Treatment

Immunotherapy has expanded therapeutic options in several gynecologic cancers, particularly cervical and biomarker-defined endometrial malignancies.

Historically, recurrent or metastatic cervical cancer has frequently carried a median overall survival of less than one year.⁹ The introduction of immune checkpoint inhibitors has altered expectations in selected populations. Pembrolizumab-based treatment combinations have demonstrated improvements in progression-free survival and overall survival among patients with persistent, recurrent, or metastatic cervical cancer.¹⁰

The impact of immunotherapy appears strongest when treatment is matched to biologic context rather than applied broadly across all patients.

This evolution represents a larger transformation in oncology: treatment selection is increasingly driven by biomarkers rather than anatomy alone.

The Next Frontier: Combination Therapy, ADCs, and Precision Immunotherapy

Current research increasingly focuses on combining therapeutic strategies rather than relying on single-agent approaches.

Combination regimens under investigation include:

• Immunotherapy plus chemotherapy
• Immunotherapy plus PARP inhibition
• Immunotherapy plus radiation therapy
• Immunotherapy plus anti-angiogenic agents¹¹

The rationale is straightforward: targeting multiple pathways simultaneously may improve efficacy while overcoming resistance mechanisms.

Another rapidly emerging area involves antibody-drug conjugates (ADCs), therapies designed to selectively deliver cytotoxic payloads to tumors expressing specific biomarkers on their cell surface.

ADCs already play an established role in recurrent or metastatic cervical cancer and continue to expand within ovarian and other gynecologic malignancies.^12,13 Agents such as tisotumab vedotin (against Tissue factor, TF) and mirvetuximab soravtansine (against folate receptor-alpha, FRα) exemplify the increasing importance of biomarker testing because therapeutic effectiveness depends on adequate target expression.^12,13 

ADCs reinforce a broader trend in oncology: treatment is becoming progressively more individualized, with biologic profiling determining therapeutic eligibility.

Two Decades of Progress—and the Work Ahead

The past two decades have transformed gynecologic cancer care through prevention, vaccination, molecular diagnostics, targeted therapies, and immunotherapy.

Several themes emerge clearly:

• Prevention remains among the most effective strategies for reducing cancer burden.
• Earlier detection—particularly in ovarian cancer—remains an urgent unmet need.
• Molecular profiling and biomarker-guided treatment are increasingly reshaping therapeutic decisions.
• Future advances will likely depend on integrating earlier detection with precision medicine.

The future of gynecologic oncology is increasingly moving from reactive treatment toward prevention, prediction, and biologically individualized care.

If that trajectory continues, the next generation may experience not only improved survival but also dramatically lower disease burden altogether.

References

1. World Health Organization. Cervical cancer. Updated November 14, 2024. Accessed May 2026. Available at: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer 
2. International Agency for Research on Cancer (IARC). Global Cancer Observatory (GLOBOCAN): Corpus uteri cancer factsheet. Accessed May 2026. Available at: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://gco.iarc.who.int/media/globocan/factsheets/cancers/24-corpus-uteri-fact-sheet.pdf
3. American Cancer Society. Ovarian Cancer: Key Statistics. Updated 2025. Available at: https://www.cancer.org/cancer/types/ovarian-cancer/about/key-statistics.html 
4. Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet. 2019;394(10197):497–509. doi:10.1016/S0140-6736(19)30298-3 
5. Wu L, Dai ZY, Qian YH, Shi Y, Liu FJ, Yang C. Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis. Int J Gynecol Cancer. 2012 Sep;22(7):1106-12. doi: 10.1097/IGC.0b013e318263efa2. PMID: 22854652. 
6. National Cancer Institute. Multi-Cancer Early Detection Tests. Accessed May 2026. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11962340/
7. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Current version. 
8. León-Castillo A, de Boer SM, Powell ME, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 2020;38(29):3388–3397. doi:10.1200/JCO.20.00549 
9. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169–182. doi:10.1016/S0140-6736(18)32470-X 
10. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385:1856–1867. doi:10.1056/NEJMoa2112435 
11. Alvarez Secord A, O'Malley DM, Sood AK, Westin SN, Liu JF. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecol Oncol. 2021;162(2):482–495. doi:10.1016/j.ygyno.2021.05.018 
12. Coleman RL, Lorusso D, Gennigens C, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Lancet Oncol. 2021;22(5):609–619. doi:10.1016/S1470-2045(21)00056-5 
13. Moore KN, Oza AM, Colombo N, et al. Mirvetuximab soravtansine in folate receptor alpha–positive platinum-resistant ovarian cancer. N Engl J Med. 2023;389:2162–2174. doi:10.1056/NEJMoa2304261